The integrative approach utilized here where two clinical subtypes (primary vs. metastases) were compared on both genome-wide copy number and expression levels is a productive methodology for identifying metastasis-relevant genes, as reflected by our ability to define a short list of candidates that included MET receptor tyrosinase kinase and BIRC5. The veracity of IGC was further supported by validation of 6 additional candidates selected from the list based on their cancer-relevant roles in other tumor types. This evidence concerns the gene MET and neoplasm.